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Abnormal circulation in solid tumors results in hypoxia, which modulates both tumor
intrinsic malignant properties as well as anti-tumor immune responses. Given the
importance of hypoxia in glioblastoma (GBM) biology and particularly in shaping
anti-tumor immunity, we analyzed which immunomodulatory genes are differentially
regulated in response to hypoxia in GBM cells. Gene expression analyses identified the
immunosuppressive enzyme tryptophan-2,3-dioxygenase (TDO2) as the second most
downregulated gene in GBM cells cultured under hypoxic conditions. TDO2 catalyses
the oxidation of tryptophan to N-formyl kynurenine, which is the first and rate-limiting
step of Trp degradation along the kynurenine pathway (KP). In multiple GBM cell lines
hypoxia reduced TDO2 expression both at mRNA and protein levels. The downregulation
of TDO2 through hypoxia was reversible as re-oxygenation rescued TDO2 expression.
Computational modeling of tryptophan metabolism predicted reduced flux through
the KP and lower intracellular concentrations of kynurenine and its downstream
metabolite 3-hydroxyanthranilic acid under hypoxia. Metabolic measurements confirmed
the predicted changes, thus demonstrating the ability of the mathematical model to
infer intracellular tryptophan metabolite concentrations. Moreover, we identified hypoxia
inducible factor 1α (HIF1α) to regulate TDO2 expression under hypoxic conditions, as
the HIF1α-stabilizing agents dimethyloxalylglycine (DMOG) and cobalt chloride reduced
TDO2 expression. Knockdown of HIF1α restored the expression of TDO2 upon cobalt
chloride treatment, confirming that HIF1α controls TDO2 expression. To investigate the
immunoregulatory effects of this novel mechanism of TDO2 regulation, we co-cultured
isolated T cells with TDO2-expressing GBM cells under normoxic and hypoxic conditions.
Under normoxia TDO2-expressing GBM cells suppressed T cell proliferation, while
hypoxia restored the proliferation of the T cells, likely due to the reduction in kynurenine
levels produced by the GBM cells. Taken together, our data suggest that the regulation of
TDO2 expression by HIF1α may be involved in modulating anti-tumor immunity in GBM.
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INTRODUCTION
More than 60 years ago, Thomlinson and Gray postulated the
occurrence of hypoxic regions in solid tumors (1). Initial interest
in studying hypoxia in tumors was due to the realization that
hypoxic cells are more resistant to radiotherapy (2) resulting
in adverse clinical outcomes for the patients. Measurements
of intra-tumoral oxygen levels revealed a highly heterogeneous
hypoxic landscape within a tumor. The oxygen concentration in
moderately hypoxic regions was determined to be ∼1% oxygen
(O2), while in severely hypoxic tumor regions it fell below 1%
O2 (3).
Cells under hypoxic conditions are known to shut down
non-essential processes by chromatin modifications and a global
downregulation of gene expression (4), while simultaneously
genes needed for cell survival under oxygen limitation are
upregulated through hypoxia inducible transcription factors
(HIFs) (5). The most well-known HIF family member HIF1α
is degraded under normoxic conditions by the action of
prolyl-hydroxylase (PHD) enzymes. However, under hypoxic
conditions PHD function is inhibited, thus stabilizing HIF1α and
activating the expression of its target genes (6). Furthermore,
HIF1α can also inhibit the expression of genes during
hypoxia (7).
Similar to other solid tumors, the most aggressive primary
brain tumor, glioblastoma multiforme (GBM), is prone to severe
hypoxia. GBM are characterized by the presence of necrotic foci
and surrounding severely hypoxic pseudopalisades consisting
of outwardly migrating GBM cells trying to escape the core
hypoxic regions (8). Measurements of O2 levels in tumors from
14 GBM patients revealed a median O2 level of 0.7% (9). Bio-
availability of oxygen to a tumor cell in a solid tumor depends
on a number of factors such as the distance of the tumor cell
from the nearest blood vessel and diminished blood supply due to
the abnormal vasculature found in tumors (10, 11). Irrespective
of the factors causing hypoxic stress, hypoxia has been shown
to drive established hallmarks of cancer progression in GBM
such as inhibition of cell death (12), induction of angiogenesis
(13), activation of endothelial to mesenchymal transition (14),
modulation of cellular metabolism (15), and tumor immune
escape (16).
Of note, hypoxic regions of solid tumors often harbor a large
number of immunosuppressive cells, which inhibit anti-tumor
immune responses (17). Tumor hypoxia in GBM has been shown
to exert immune suppression by activation of regulatory T cells
(Tregs) (18). HIF1α-mediated gene regulation is involved in
promoting hypoxic suppression of anti-tumor immunity (19, 20).
For instance, HIF1α induces the expression of the inhibitory
immune checkpoint regulator programmed death-ligand 1 (PD-
L1), which facilitates the suppression of anti-tumor immune
effects (21, 22). Furthermore, hypoxia also obstructs anti-tumor
immunity by reduction of tumor cell MHC presentation and the
tumor cell expression of chemokines essential for immune cell
infiltration (23).
In light of the important role played by hypoxia in GBM
biology and particularly in modulating anti-tumor immune
responses, we analyzed GBM cells for genes involved in
the regulation of anti-tumor immunity that are differentially
regulated upon hypoxia. We find that hypoxia significantly
reduces the expression of the immunosuppressive enzyme
tryptophan-2,3-dioxygenase (TDO2). TDO2 catalyses the first
step of tryptophan (Trp) catabolism along the kynurenine
pathway (KP) and is known to play an important role in
GBM as it promotes tumor cell motility and suppresses anti-
tumor immune responses via production of Trp metabolities that
activate the aryl hydrocarbon receptor (AHR) (24).
MATERIALS AND METHODS
Cell Culture
Human GBM cell lines A172, U-87MG, and LN-18 were
obtained from ATCC. Cells were cultivated in DMEM (Gibco)
containing 10% FBS (Gibco), 2mM Glutamine (Gibco), 1mM
Sodium Pyruvate (Gibco), 100µg/ml Streptomycin, and 100
U/ml Penicillin (Gibco). Cells were authenticated by Multiplex
Cell Authentication service (Multiplexion GmbH) and were
routinely monitored using the Venor R© GeMClassic mycoplasma
detection kit (Minerva Biolabs). Twenty-four hours after cell
seeding a medium change was done following which, various
treatments were carried out. Unless stated otherwise, cells
were normally cultivated at normoxic conditions i.e., 18.6% O2
concentration (conc.) (25) in a SANYO MCO-18AIC incubator
with 5% CO2 and at 37
◦C.
Long Term Hypoxic Exposure
A172, U-87 MG, and LN-18 cells in T25 flasks containing
5ml medium, were subjected to either normoxic or hypoxic
conditions for 3, 5, 8, and 10 days. For hypoxic conditions (i.e.,
1% O2) cells were placed in the Labotect incubator C42. For
each time point, cells were seeded in duplicates; one of the
flasks was incubated in normoxic conditions and served as a
control for the other flask incubated under hypoxic conditions.
At the indicated time points, 1ml culture supernatant from each
treatment was harvested and used for metabolic measurements.
Subsequently, the cells were harvested by trypsinization in 1.5ml
PBS. The cell count of the harvested cells was measured using 10
µl of cell suspension and Trypan Blue dye (Gibco) in a 1:1 ratio
with an automated Cell Counter (Countess, Invitrogen). The
remaining cells were further processed for either RNA, protein
or intracellular metabolite extraction.
Treatment With Hypoxia Mimetics
HIF1α protein stabilization was attained by using the hypoxia
mimetic compounds dimethyloxalylglycine (DMOG) and cobalt
chloride (CoCl2). DMOG was obtained from Frontier Scientific
Inc. and reconstituted in 100% ethanol (Sigma). Cells were
treated such that the final DMOG concentrations of 0.5, 1, 2, and
3mM were obtained according to the treatment specifications.
EtOH was used as carrier control. A second hypoxia mimetic
agent, cobalt chloride (CoCl2) was obtained from Sigma and
reconstituted in ddH2O. Cells were treated for 24 h such that a
final treatment concentration of 100, 150, 200, 250, and 300µM
of CoCl2 was obtained.
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RNA Isolation and Quantitative (q)RT-PCR
Total RNA was isolated using the RNAeasy Mini Kit (Qiagen).
cDNA was reverse transcribed from 1 µg total RNA using
the High Capacity cDNA reverse transcriptase kit (Applied
Biosystems). cDNA amplification was performed using the
SYBR Select Master Mix (Thermo Fisher Scientific) during the
(q)RT-PCR on a StepOnePlus real-time PCR system (Applied
Biosystems). For all (q)RT-PCRmeasurements 18s RNAwas used
as a housekeeping gene for normalization. (q)RT-PCR primers
for a gene were designed using Primer Blast (NCBI), such that on









Protein Isolation and Western Blots
Total protein was harvested using ice-cold RIPA lysis buffer
(1% IGEPAL/NP40, 12mM sodium-deoxycholate, 3.5mM
sodium dodecyl sulfate (SDS) supplemented with a protease and
phosphatase inhibitor (Roche/Sigma-Aldrich). The Bradford
protein assay (Biorad) was employed for total protein content
measurement and subsequent normalization between samples
across one experiment. Protein samples were separated using a
10% SDS-PAGE gel and transferred onto an activated 0.45µm
PVDF membrane (Sigma-Aldrich), subsequently the membrane
was blocked with 5% BSA for 30min and incubated with primary
antibodies overnight. The primary antibodies were used in
1:1000 dilution for mouse anti-human TDO2 (#TA504730,
Origene), rabbit anti-human NDRG1 (#HPA006881, Sigma),
and rabbit anti-human Tubulin (#ab108629, Abcam plc.).
Membranes were subsequently incubated for 1 h with 1:5000
diluted HRP-conjugated secondary antibodies (anti-rabbit
ab.: #GENA9340-1M, anti-mouse ab.: #GENXA931, both
from GE Healthcare). Either Pierce R© ECL Western Blotting
Substrate or SuperSignal R© West Femto Maximum Sensitivity
Substrate (both Thermo Scientific) were used to generate the
signals, which were captured either on an autoradiography
film (Amersham Hyperfilm, GE Healthcare) or on the
ChemiDoc XRS+ (Bio-Rad Laboratories) using Image Lab
Software 5.2.1.
siRNA-Mediated HIF1α Knockdown
siRNA stocks (20µM) were prepared by reconstituting ON-
TARGETplus Human SMARTPOOL siRNA reagent targeting
HIF1α (Dharmacon) in sterile PBS in accordance to the
manufacturer’s recommended ratio. ON-TARGETplus Non-
targeting Pool siRNA (Dharmacon) was used as a control.
siRNA transfection mix was prepared using siRNA stocks and
Lipofectamine RNAiMAX (Thermo Fisher Scientific) according
to the manufacturer’s protocol. Cells were treated with the
transfection mix for 24 h, which was followed by a fresh
medium change and incubation with cobalt chloride for 24 h
before harvest.
High Performance Liquid Chromatography
(HPLC)
For Trp and Kyn measurements (Figures 2A,B) in cell culture
supernatants, 72% trichloroacetic acid (Sigma-Aldrich) was
added in a ratio of 162.8 µl per 1ml of supernatant for protein
precipitation. Samples were then centrifuged at full speed for
12min, following which the supernatants were analyzed in a
Dionex Ultimate R© 3000 uHPLC (Thermo Scientific, Waltham,
MA, USA) by chromatographic separation. An AccucoreTM aQ
column (Thermo ScientificTM) with 2.6µm particle size with
a gradient mobile phase consisting of 0.1% trifluoroacetic acid
(TFA) in water (A) and 0.1% TFA in acetonitrile (B) was
utilized for separation of Trp and Kyn, which were detected
at UV emission spectra of 280 and 365 nm, respectively. The
ChromeleonTM 7.2 Chromatography Data System (Thermo
ScientificTM DionexTM) was used for data analysis.
For intracellular analyses of Trp and Trp-derived compounds
(Figure 2C), the samples were rapidly frozen in liquid nitrogen
following trypsinization and pelleting of harvested cells.
Subsequently, metabolites were extracted with 0.1ml 6%
perchloric acid per million of cells in an ultrasonic ice-bath
for 10min. For analyses of extracellular content, supernatants
were mixed with an equal volume of 12% perchloric acid
and incubated on ice for 10min. Prior analysis, samples were
centrifuged for 10min at 4◦C and 16.400 g to precipitate
proteins and to remove remaining cell debris. Metabolites were
separated by reversed phase chromatography on an Acquity
HSS T3 column (100 × 2.1mm, 1.7µm, Waters) connected
to an Acquity H-class UPLC system (Waters). The column
was heated to 37◦C and equilibrated with 5 column volumes
of 100% solvent A (20mM sodium acetate, 3mM zinc acetate,
pH 6) at a flow rate of 0.55ml min−1. Clear separation of Trp
and Trp-derived compounds was achieved by increasing the
concentration of solvent B (Acetonitrile) in solvent A as follows:
4min 0% B, 10min 5% B, 13min 15% B, 15min 25% B, and
return to 0% B in 3min. Trp, 3HAA, KynA and tryptamine
were detected by fluorescence (Acquity FLR detector, Waters,
excitation: 254 nm, emission: 401 nm). Kyn and OH-Kyn
were determined by simultaneous recording of absorption at
365 nm (Acquity PDA detector, Waters). For quantification,
ultrapure standards were used (Sigma). Data acquisition
and processing was performed with the Empower3 software
suite (Waters).
Microarray Analysis
RNA was harvested after 5 days from the control and hypoxic
cells, using the RNAeasy Mini Kit (Qiagen). Labeled ss-cDNA
was generated from 100 ng total RNA using the Affymetrix
WT PLUS Reagent Kit, as per the manufacturer’s instructions.
Subsequently, 5.5 µg of fragmented and labeled ss-cDNA
were hybridized for 17 h at 45◦C on Affymetrix Human Gene
2.0 ST chip following the manufacturer’s instructions. The
Affymetrix GeneChip R© Scanner 3000 was used for scanning
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the hybridized chips according to the GeneChip R© Expression
Wash, Stain and Scan Manual for Cartridge Arrays (P/N
702731). The Raw CEL files were imported from disk followed
by RMA normalization and summarization using the oligo
package and were annotated at the probeset level using
NetAffx (26). Differential gene expression was conducted by
fitting a linear model and estimating a moderated t-statistic
followed by eBayes adjustment as described in the limma
package (27, 28). All analyses were run in R, version 3.4.4
(https://cran.r-project.org/) and Bioconductor version 3.6
(https://bioconductor.org/). All graphical representations
were generated using ggplot2, ggpubr, and RcolorBrewer.
All datasets have been made publicly available in the Gene
Expression Omnibus (GEO) repository under accession
number GSE138535.
Modeling of Trp Metabolism
To simulate Trp metabolism in A172 cells, we employed
the previously published comprehensive kinetic model of Trp
metabolism (29). Microarray data previously generated for A172
cells exposed to normoxia or hypoxia for 5 days, were integrated
into the Trp model using SBMLmod as described previously
(30). No transporters and no external metabolites were used.
Instead the concentration of cellular Trp was set to the measured
intracellular concentration, assuming a cell volume of 10 pL.
Steady-state concentrations and fluxes were calculated using the
steady state task of COPASI 4.26 (31).
Proliferation Measurements in T Cell
Co-cultures
The functional characterization of PBMC from healthy donors
was approved by the Ethics Committee of the University of
Heidelberg. PBMC isolation was carried by density-gradient
centrifugation and T cells were enriched using the MojoSort
Human CD4T cell isolation kit (Biolegend) according to the
manufacturer’s instructions. T cells were cultured in 96 well plates
either alone or in a co-culture with A172 cells in RPMI1640
(Thermo Fisher Scientific) containing 10% FCS in the presence of
5µg/ml phytohaemagglutinin (PHA) (Sigma) and 1 U/µl rhIL-
2 (Novartis). All cultures were performed in duplicate sets, one
set under normoxia and the second under hypoxia. A glove
box (Coylab) and an incubator (Heracell 150i, Thermo Fisher
Scientific) with oxygen level regulation were used for ensuring
continued hypoxia conditions during all steps of culturing.
PKH26 (Sigma-Aldrich) was used to label T cells prior to culture.
After 6 days of culturing, PKH26 mean fluorescence intensity
(MFI) was measured by flow cytometry (BD FACSCanto II (BD
Biosciences). The degree of reduction in PKH26 fluorescence
intensity reflected the number of cell divisions undergone by the
cells. Suppression of T cell proliferation by hypoxia wasmeasured
by calculating the ratio between the PKH26 MFI of T cell co-
cultured with A172 cells and the PKH26 MFI of T cells cultured
alone, for both normoxia and hypoxia culture conditions.
Statistical Analysis
GraphPad Prism v5.04 (GraphPad Software Inc.) was used for
performing statistical analysis. For single comparisons between
two datasets, two-tailed unpaired Student’s t-test was utilized.
Rank sum analysis by the Mann–Whitney U-test was carried
out wherever necessary. For multiple comparisions, one-way
ANOVA with Tukey’s multiple comparisons test was employed.
Data was collected from at least three independent experiments.
All data are plotted as mean ± SEM, unless stated otherwise.
Differences with a p ≤ 0.05 were considered to be statistically
significant (ns: not significant i.e., p> 0.05; ∗p≤ 0.05; ∗∗p≤ 0.01;
∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001).
RESULTS
TDO2 Expression Is Suppressed Under
Hypoxia
To investigate if hypoxia differentially regulates genes that
play a role in anti-tumor immune responses in GBM cells, we
performed microarray analysis of A172 GBM cells exposed to
5 days of hypoxia (1% O2) as compared to cells cultured in
normoxia (18.6% O2) (GSE138535). Analysis of the microarray
data revealed tryptophan-2,3-dioxygenase (TDO2) to be the
second most downregulated gene under hypoxia (Figure 1A,
Supplementary Table 1). TDO2 is an immunosuppressive
enzyme, whose metabolic products have been shown to
modulate anti-tumor immune responses by inhibition of T
cell proliferation as well as induction of apoptosis in T cells
(32, 33). Apart from TDO2, other immune-regulatory genes,
such as TLR3 and CCL2 were also strongly downregulated under
hypoxia (Supplementary Table 1). However, in the present study
we focussed our attention on TDO2, the strongest differentially
regulated gene candidate among the genes with known effects
on immune responses. TDO2 integrates molecular O2 into Trp
to generate formyl-kynurenine, which is further converted to
kynurenine (34). Therefore, reduced O2 concentrations under
hypoxia would be expected to affect the enzymatic activity of
TDO2, however our microarray data revealed that also the
expression of TDO2 may be reduced upon hypoxia in GBM cells.
To validate the results of the microarray, we next performed
qRT-PCR measurements. To test for the presence of hypoxia
we assayed N-myc downstream regulated 1 (NDRG1), a gene
known to be upregulated under hypoxia in GBM (35, 36), as a
surrogate hypoxia marker that was also significantly upregulated
by hypoxia in the microarray (Supplementary Table 1). Analysis
of mRNA transcript levels in A172 cells exposed to hypoxic
conditions for different durations, confirmed the presence of
hypoxia as NDRG1 was significantly upregulated (Figure 1B,
left). Further, the qRT-PCR measurements confirmed the
result of the microarray analysis, as a significant reduction
in TDO2 mRNA levels was observed at all-time points upon
hypoxic exposure (Figure 1B, right). Downregulation of TDO2
mRNA in response to hypoxia was not limited to A172
cells, but was also observed in U-87MG and LN-18 GBM
cells (Figures 1C,D). Western blot analysis of all three GBM
cell lines exposed to either normoxia or hypoxia revealed
that TDO2 protein expression was reduced under hypoxia,
while expression of the hypoxia surrogate marker NDRG1
was increased (Figure 1E). To investigate whether the hypoxic
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FIGURE 1 | Hypoxia reversibly downregulates tryptophan-2,3-dioxygenase (TDO2) expression in GBM cells. (A) Volcano plot showing differentially regulated genes in
A172 cells upon exposure to 5 days of hypoxia compared to 5 days normoxic controls. (B) qRT-PCR analysis of NDRG1 (left) and TDO2 (right) mRNA expression in
A172 cells after 3, 5, 8, or 10 days of exposure to either normoxia (white) or hypoxia (back). (C) qRT-PCR analysis of NDRG1 (left) and TDO2 (right) mRNA expression
(Continued)
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FIGURE 1 | in U-87MG cells after 5 days of either normoxia (white) or hypoxia (black) exposure. (D) qRT-PCR analysis of NDRG1 (left) and TDO2 (right) mRNA
expression in LN-18 cells after 5 days of either normoxia or hypoxia. (E) Western blot analysis of TDO2 and NDRG1 protein expression in A172, U-87MG, and LN-18
cells subsequent to 5 days normoxia or hypoxia. α-Tubulin protein expression was used as a loading control. (F) NDRG1 (left) and TDO2 (right) mRNA expression in
A172 cells analyzed by qRT-PCR after exposure to hypoxia for 5 days followed by re-oxygenation for 3 days under normoxic conditions (ND3). Data from at least three
independent experiments are expressed as mean ± S.E.M. Statistical significance was assumed at p < 0.05 (**p < 0.01, ***p <0.001, ****p ≤ 0.0001). n.s.,
not significant.
downregulation of TDO2 expression can be restored by re-
oxygenation, we subjected A172 cells to 3 days of normoxia
after 5 days of hypoxia. Re-oxygenation completely restored the
expression of TDO2 (Figure 1F), indicating that the observed
hypoxic downregulation of TDO2 is reversible.
Hypoxia-Mediated TDO2 Downregulation
Reduces Flux Through the KP
TDO2 catalyses the first step of Trp degradation along the KP
(37). However, after establishing the regulatory effects of hypoxia
on TDO2 expression, we aimed to investigate effects of reduced
oxygen on Trp degradation and KPmetabolite production, which
likely results from both the hypoxia-mediated reduction in TDO2
expression and possibly also reduced TDO2 catalytic activity
due to O2 limitation. Analysis of supernatants harvested from
the long-term hypoxia experiments with A172 cells (shown in
Figure 1B), revealed that cells growing under hypoxic conditions
produced less Kyn than the cells cultured under normoxia
(Figure 2A). This reduction in Kyn production corresponded to
the high amount of Trp that remained present in the supernatants
of the hypoxic cells (Figure 2B). Taken together, these results
indicate that hypoxia downregulates Trp catabolism.
We next hypothesized that the reduced amount of Kyn
produced by TDO2 upon hypoxia should affect the metabolic
flux of the entire KP. We therefore performed computational
modeling of Trp metabolism to predict the steady state
fluxes and metabolite concentrations in the KP. To this
end, gene expression data from A172 GBM cells cultivated
under either hypoxia or normoxia (see Figure 1A) was
integrated into the previously mentioned mathematical model
of Trp metabolism (29). In line with our hypothesis, the
model predicted a significantly decreased Trp catabolic flux
mainly caused by the reduced enzymatic flux through TDO2,
while the flux through DOPA decarboxylase (DDC) remained
unperturbed (Figure 2C). Further, reduced metabolic flux was
also predicted for downstream enzymes that degrade Kyn, such
as the kynurenine aminotransferases (KATs) and kynurenine-
3-monooxygenase (KMO), which generate kynurenic acid
(KynA) and 3-hydroxy-anthranilic acid (3HAA), respectively
(Figure 2C). This reduced metabolic flux under hypoxia through
major enzymes of the KP resulted in reduced simulated
intracellular concentrations not only of Kyn but also of its
downstream metabolite 3HAA (Figure 2C, gray plots). In
contrast, the simulated production of Trp metabolites not
directly dependent on TDO2 activity such as tryptamine were
predicted to remain unaffected under hypoxia (Figure 2C,
gray plots).
To validate the predictions of the mathematical model
of Trp metabolism, we analyzed the changes in intracellular
concentrations of Trp metabolites in the A172 GBM cells after
5 days of exposure to hypoxia. In line with the simulations,
the intracellular concentrations of the KP metabolites Kyn and
3HAA were significantly reduced under hypoxia (Figure 2C,
black plots). Although intracellular KynA concentrations were
reduced, this decrease failed to attain significance (Figure 2C,
black plots). Furthermore, confirming the predictions, the
intracellular tryptamine concentrations remained unchanged
under hypoxia. In the cell supernatants no changes in 3HAA
and KynA levels were observed under hypoxia and tryptamine
was undetectable (Supplementary Figure 1). However, in line
with our simulations and previous observations, Trp levels
in the supernatants increased significantly under hypoxic
conditions consistent with the significant decrease in Kyn
production (Supplementary Figure 1). Taken together, these
results confirm our computational predictions and show that
hypoxic downregulation of TDO2 expression reduces flux
through the KP.
TDO2 Expression Is Reduced Upon
Stabilization of HIF1α by Chemical Hypoxia
Mimetics
Hypoxia mediates most of its effects through the master regulator
HIF1α, however a HIF1α independent global downregulation
of gene expression by hypoxia has also been described (4).
Therefore, we next investigated if HIF1α plays a role in the
hypoxia-mediated downregulation of TDO2. For this, we
stabilized HIF1α protein under normoxic conditions by the use
of chemical hypoxia mimetics such as dimethyloxalylglycine
(DMOG) or cobalt chloride (CoCl2). Microarray analysis
of A172 cells incubated for 24 h in the presence of 3mM
DMOG (GSE138535), revealed that TDO2 gene expression was
strongly downregulated upon HIF1α stabilization (Figure 3A,
Supplementary Table 2). qRT-PCR analysis of A172 cells
exposed to a range of DMOG concentrations, confirmed
the microarray data, as elevated NDRG1 mRNA levels upon
DMOG exposure (Figure 3B, left) corresponded to a decrease
in TDO2 mRNA expression at tested DMOG concentrations
(Figure 3B, right). Analysis of the mRNA expression of
A172 cells exposed to a second hypoxia mimetic, cobalt
chloride (CoCl2), also significantly reduced TDO2 mRNA
expression at concentrations of 250µM CoCl2 and above
(Figure 3C, right). Correspondingly, mRNA levels of the
surrogate hypoxia marker NDRG1 were elevated upon exposure
to 200µM CoCl2 and above (Figure 3C, left). In summary,
these results indicate that TDO2 expression is regulated
by HIF1α.
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FIGURE 2 | Reduced TDO2 expression leads to reduced Trp flux through the KP. (A) uHPLC chromatogram (left) showing Kyn measured in supernatants of A172
cells exposed to 5 days of either normoxia (blue) or hypoxia (red). Quantification of Kyn measurements (right) in supernatants of A172 cells cultured either under
normoxia (white) or hypoxia (black) for 3, 5, 8, or 10 days. (B) uHPLC chromatogram (left) showing Trp measured in supernatants of A172 cells exposed to 5 days of
either normoxia (blue) or hypoxia (red). Quantification of Trp (right) in A172 cell supernatants cultured either under normoxia (white) or hypoxia (black) for 3, 5, 8, or 10
days. (C) Scheme depicting the most prominent changes in the flux through the Trp degradation pathway upon exposure to hypoxia (blue plots). Microarray data from
A172 GBM cells upon 5 days of hypoxia exposure was integrated into a computational model of Trp metabolism to calculate the fluxes through different enzymes and
the general flux through the entire pathway (blue plots) as well as to predict the intracellular metabolite concentrations (gray plots). These intracellular predictions were
validated by measurements of the intracellular concentrations (black plots). Data from at least three independent experiments are expressed as mean ± S.E.M.
Statistical significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01, ***p <0.001). n.s., not significant.
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FIGURE 3 | HIF1α stabilization recapitulates hypoxia-mediated reduction in
TDO2 expression. (A) Volcano plot showing differentially regulated genes in
A172 cells exposed to 3mM DMOG for 24 h compared to DMSO controls. (B)
qRT-PCR analysis of NDRG1 (left) and TDO2 (right) mRNA expression in A172
cells exposed to 0.5, 1, 2, and 3mM DMOG for 24 h. (C) qRT-PCR analysis of
NDRG1 (left) and TDO2 (right) mRNA expression in A172 cells after treatment
with 100, 150, 200, 250, and 300µM of a second HIF1α stabilizing agent,
CoCl2, for 24 h. Data from at least three independent experiments are
expressed as mean ± S.E.M. Statistical significance is assumed at p < 0.05
(*p < 0.05, **p < 0.01, ***p < 0.001).
siRNA-Mediated Silencing of HIF1α
Restores TDO2 Expression
We next investigated whether the absence of HIF1α can abrogate
the observed reduction in TDO2 expression. siRNA-mediated
silencing of HIF1α resulted in a significant reduction in HIF1α
mRNA (Figure 4A). The reduction of HIF1α was functionally
relevant as it prevented the mRNA induction of the surrogate
hypoxia marker NDRG1 upon exposure to CoCl2 (Figure 4B).
Most importantly, however, the suppression of TDO2 mRNA
expression upon CoCl2 exposure was abrogated in the absence of
HIF1α (Figure 4C). Finally, Western blot analysis of A172 cells
under the above conditions revealed a complete rescue of TDO2
protein expression upon knockdown of HIF1α (Figure 4D).
Taken together, these results confirm that HIF1α controls TDO2
expression in GBM cells.
Hypoxia Impairs the Ability of Tumor Cells
to Suppress T Cell Proliferation
TDO2 expression in tumor cells enables them to effectively
downregulate the proliferation and thus the anti-tumor activity
of infiltrating T cells through production of KP metabolites (32)
and the depletion of Trp (38, 39). As our results demonstrate
that TDO2 expression is significantly reduced in GBM cells
under hypoxic conditions, we next investigated the effect of
hypoxia on the proliferation of activated T cells in the presence
of A172 GBM cells cultured under either normoxia or hypoxia.
Under normoxic conditions, the GBM cells in the co-culture
system were clearly capable of suppressing T cell proliferation
as compared to the normoxic T cell mono-cultures (Figure 5A).
However, under hypoxic conditions the previously observed
T cell suppression by GBM cells was reduced (Figure 5B).
Quantification of T cell proliferation expressed as PKH26 mean
fluorescent intensity (MFI) revealed that exposure to hypoxia
significantly reduced the T cell suppressive capacity of A172
GBM cells in the co-culture system (Figure 5C).
DISCUSSION
Over the past decades, the role of hypoxia in shaping the
tumor microenvironment and its contribution to tumor cell
intrinsic properties as well as anti-tumor immunity has beenwell-
documented (17). Hypoxia is a frequently occurring feature in
most solid tumors includingGBM,where it not only drives tumor
malignancy but also determines tumor morphology (8).
Here, we set out to investigate the role of hypoxia
in controlling GBM-derived factors that impact anti-tumor
immune responses. Gene expression analysis identified TDO2
as the immunomodulatory factor most strongly regulated in
response to hypoxia. TDO2 is a heme containing dioxygenase
enzyme, which catalyses the first step of the KP, namely
the conversion of Trp to formyl-kynurenine (32). Trp is
the least abundant essential amino acid in humans, which
in addition to its role in protein synthesis also functions
as the precursor for diverse neurotransmitters, hormones
and vitamins including serotonin, tryptamine, melatonin, and
nicotinamide (40, 41). Trp catabolism along the KP is a well-
known modulator of immune responses. Initially identified
as an immunosuppressive mechanism preventing the rejection
of allogeneic fetuses (42), Trp catabolism has also been
implicated in neuropsychiatric disorders (43, 44), auto-immune
and inflammatory diseases (45, 46).
Moreover, human cancers often express high levels of
indoleamine-2,3-dioxygenase 1 (IDO1) and/or TDO2, the initial
Trp-catabolic enzymes of the KP (37). TDO2, for instance is
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FIGURE 4 | TDO2 expression is rescued upon siRNA-mediated HIF1α silencing. (A) qRT-PCR analysis of A172 cells for HIF1α mRNA levels, 24 h post treatment with
CoCl2 and 48 h post treatments with either non-targeting siC or siRNA targeting HIF1α. (B) qRT-PCR analysis of A172 cells as in (A). showing NDRG1 mRNA levels
post HIF1α silencing and CoCl2 treatment. (C) TDO2 mRNA levels analyzed by qRT-PCR in A172 cells treated as in (A,B). (D) Western blot analysis of TDO2 and
NDRG1 in A172 cells subsequent to siRNA-mediated HIF1α silencing and CoCl2 treatment. β-Actin was used as loading control. Data from at least three independent
experiments are expressed as mean ± S.E.M. Statistical significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001). n.s., not significant.
expressed in diverse tumor entities including breast cancer,
bladder cancer, hepatocellular carcinoma, melanoma, non-small
cell lung cancer, ovarian carcinoma, renal cell carcinoma, and
GBM, where it promotes tumor cell motility and suppresses T
cell proliferation and function (24, 47, 48). As Trp catabolism
along the KP plays an important tumor-promoting role, this has
resulted in interest toward targeting the enzymes of this pathway
for cancer therapy (49).
Abnormal or inadequate vasculature in GBM results in
formation of regions that have restricted nutrient and oxygen
supply (50). Malignant cells in these nutrient-deprived hypoxic
regions adapt to survive by profound metabolic reprogramming.
In human GBM cells, numerous genes involved in global cellular
metabolism are downregulated in response to hypoxia (15). This
enables the cells to conserve nutrients in order to redirect them
toward essential life-sustaining processes. Hypoxic regions in
GBM, due to their nutrient-restricted microenvironment, tend
to have a limited supply of Trp, which would dictate that cells
conserve Trp under hypoxia. Here, we show that indeed upon
hypoxic exposure GBM cells reversibly downregulate TDO2
expression (Figures 1A–E), which is restored upon availability
of oxygen (Figure 1F). This reversibility may enable tumor
cells to effectively regulate Trp catabolism as necessary under
cyclic hypoxia, which has been described to frequently occur
during tumor progression and metastasis (51). In line with
the downregulation of TDO2, the amount of downstream Kyn
produced under hypoxia was reduced significantly (Figure 2A),
corresponding to higher levels of Trp remaining in the
extracellular space (Figure 2B).
In humans, Trp can be degraded by a number of enzymes
along different metabolic pathways, however a majority of the
available free Trp has been reported to be degraded via the
KP (37). Therefore, we hypothesized that hypoxic control of
TDO2 expression, might influence global Trp flux in a tumor
cell. We employed a previously described computational model
(29) to integrate gene expression data in order to predict
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FIGURE 5 | Ability of GBM cells to suppress T cell proliferation is reduced under hypoxia. (A) PKH26-labeled CD4+ T cells were stimulated and cultured for 6 days
either alone or in co-culture with A172 GBM cells. Histogram from a representative experiment where cultures were placed under normoxia (line histogram represents
T cells cultured alone, while filled histogram represents T cells co-cultured with A172 cells). (B) Experimental setup as described in (A), except that the cells were
cultured under hypoxia. (C) Plot showing the change in the ratio between the PKH26 mean fluorescence intensity (MFI) of T cells co-cultured with A172 GBM cells vs.
those cultured alone, either under normoxia (white) or hypoxia (black). Data from at least three independent experiments are expressed as mean ± S.E.M. Statistical
significance is assumed at p < 0.05 (***p < 0.001).
changes in Trp metabolism under hypoxia. Our predictions
revealed that indeed under hypoxia, the global Trp flux was
significantly reduced (Figure 2C, blue plots). This reduction
upon hypoxia can be attributed to the reduction in metabolic flux
through TDO2 and consequently other downstream enzymes
in the KP (Figure 2C, blue plots). In line, the computational
model predicted that intracellular concentrations of Kyn and its
downstream metabolite 3HAA were significantly reduced under
hypoxia (Figure 2C, gray plots). In contrast, the flux through
enzymes outside the KP, such as DDC, which degrades Trp to
the neuromodulator tryptamine, remained virtually unperturbed
(Figure 2C, blue plots). These predictions substantiate our
hypothesis, that under hypoxia tumor cells downregulate TDO2
expression in order to conserve Trp.
To validate the computational predictions, we next measured
intracellular metabolite concentrations of A172 GBM cells
cultured under the same conditions as for the microarray
analysis. The measured intracellular concentrations of Kyn and
other Trp metabolites reflected the exact pattern of the predicted
concentrations (Figure 2C, black plots), demonstrating that
prediction of Trp metabolite concentrations accurately reflects
their relative changes. The measurements showed that under
hypoxic conditions the intracellular pool of Trp remains largely
unchanged due to a significant reduction in the flux through
TDO2. The latter was reflected by a reduced production of Kyn
and downstream metabolites, while the concentration of other
Trp metabolites such as tryptamine was unaltered (Figure 2C).
Previously, we have shown that tumor cells in a nutrient-deficient
but normoxic microenvironment upregulate the expression of
tryptophanyl-tRNA synthetase to better utilize the available Trp
pool for protein synthesis (52). Taken together, our current
results establish the presence of a second adaptation to limited
Trp availability under nutrient stress, where tumor cells conserve
Trp by downregulation of TDO2 under hypoxic conditions.
Reduced Kyn levels in response to hypoxia have previously
been attributed in tumor cells and fibroblasts to reduced
expression and activity of IDO1 (53–55), which catalyzes the
same reaction as TDO2. The presence of chemokines or
chemokine-producing immune cells can however increase the
expression of IDO1 under hypoxia (54, 56). Other studies have
also reported the upregulation of IDO1 expression upon hypoxic
exposure or HIF1α stabilization in neural and immune cells (57–
59). Taken together, these studies indicate that the regulation
of IDO1 under hypoxic conditions is highly cell type specific
and also depends upon microenvironmental factors such as
immune cell infiltration. Elbers and colleagues also previously
described hypoxia-mediated downregulation of Trp metabolism,
which they attributed to reduced TDO2 enzymatic activity under
hypoxia (60). The authors used recombinant TDO2 protein
in an overexpression system to arrive at the aforementioned
conclusions. However, our results provide evidence for the
existence of a transcriptional mechanism regulating TDO2-
mediated Trp degradation under hypoxia.
Most biological effects of TDO2 including its
immunosuppressive actions can be attributed either to the
depletion of Trp, which activates nutrient sensing mechanisms
such as GCN2 (61) or to the accumulation of downstream
KP metabolites. The KP metabolite 3HAA modulates immune
functions by enhancing the differentiation of Tregs, reducing
T cell proliferation and inducing T cell death (62–64). 3HAA
can also interfere with the anti-tumor activity of macrophages
by inhibiting their NO production (64). Moreover, 3HAA can
be converted further along the KP to quinolinic acid (QA)
(65), which can serve as a precursor for NAD+ biosynthesis
(66–68). In line with immunosuppressive effects of 3HAA, its
metabolic product QA can also modulate immune cell function
by suppressing T cell proliferation and increasing Tregs (64).
AHR activation accounts for many of the effects of
Trp degradation (24, 69–72). KP metabolites including Kyn,
kynurenic acid, xanthurenic acid, and cinnabarinic acid are
potent AHR activators (24, 69–72). Moreover, engagement of
nuclear coactivator 7 by 3HAA has been reported to enhance
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activation of the AHR in dendritic cells (73). AHR activation
results in AHR binding to HIF1β (ARNT), which also is a binding
partner for HIF1α upon its hypoxia-mediated stabilization.
Sharing a common binding partner increases the likelihood of
competition between the two transcription factors for ARNT
binding in scenarios where both AHR activation and HIF1α
stabilization take place. In line, reports indicate that HIF1α
stabilization adversely affects the activity and downstream gene
regulation subsequent to AHR activation in an ARNT-dependent
fashion (74). Thus, hypoxia could counteract TDO2 effects
mediated via AHR. Furthermore, in GBM, signaling through
HIF1α and AHR can crossregulate each other at several points
of contact, coordinating metabolic regulation of anti-tumor
immunity as well as tumor growth (75).
In this light, we investigated if HIF1α can also interfere
upstream of AHR by regulating TDO2 expression or whether
the observed hypoxia-mediated TDO2 downregulation is a
general HIF1α- independent hypoxia effect. We used the
hypoxia mimetic DMOG to stabilize HIF1α in A172 GBM cells
under normoxic conditions. Microarray results and qRT-PCR
measurements identified TDO2 to be the most downregulated
gene upon HIF1α stabilization by DMOG (Figures 3A,B).
Further, use of a second HIF1α stabilizing agent, CoCl2,
also resulted in a significant reduction in TDO2 expression
(Figure 3C). siRNA-mediated knockdown of HIF1α rescued
TDO2 expression (Figures 4A–D). Taken together, these results
suggest that HIF1α employs a two-pronged strategy to regulate
AHR activity, first by direct competitive binding of ARNT (74)
and second by downregulating TDO2 expression, thus reducing
the concentration of AHR-activating Trp-metabolites.
Although lower oxygen levels are essential for immune
cell maturation, extreme pathological hypoxia especially in a
tumor acts as an effective immunosuppressive strategy, helping
tumors escape immune surveillance (20). TDO2 also helps tumor
immune evasion by activating the AHR through its downstream
metabolites (24). In light of the existence of these two distinct
modi operandi of tumors to suppress anti-tumor immunity, we
next ascertained their role in tumor immune suppression under
hypoxic conditions. Our data revealed a significant reduction
in the immune suppressive abilities of GBM cells in hypoxic
co-cultures with T cells (Figures 5A–C).
In the present study, we report a HIF1α-dependent regulatory
mechanism in GBM cells through which hypoxia can reversibly
regulate the expression of the Trp-degrading enzyme TDO2
and thus the production of known immunosuppressive onco-
metabolites. Our results further suggest that GBM cells in
their quest to give anti-tumor immunity a slip, employ the
immunosuppressive effects of both TDO2 and hypoxia in a well-
coordinated fashion. In microenvironments with ample oxygen
and nutrient availability, tumor cells can employ the TDO2-Kyn-
AHR axis to suppress the immune system. While in a nutrient-
deficient hypoxic microenvironment, where hypoxia itself keeps
the immune system in check, tumor cells in a HIF1α-dependent
fashion can downregulate TDO2 expression so as to conserve
Trp. This novel mechanism may present new insights for better
clinical management of anti-tumor immune suppression by both
TDO2 expression as well as by hypoxia.
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